DOCSLIB.ORG

Draft Alphabetical Commodity Index Bhutan Trade Classification, 2017

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Draft Alphabetical Commodity Index Bhutan Trade Classification, 2017 Department of Revenue & Customs Ministry of Finance Alphabetical Index: Bhutan Trade Classification, 2017 Explanatory Goods HS/BTC Code Notes Abaci, toy 95.03 Abcess needles, dental 90.18 Abietates 38.06 Abietic acids 38.06 Abietyl alcohol 38.06 Abrasion testing machines and appliances 90.24 Abroma augusta (textile fibres) 53.03 Abs copolymers 3903.3 39.03 Absinth (alcoholic aperitive) 22.08 Absolutes (essential oils) 33.01 33.01 Absorptiometers 90.27 Absorption drums, of glass, for hydrochloric acid 70.2 Abutilon avicennae (textile fibres) 53.03 Abutilon hemp (textile fibres) 53.03 Acacia catechu dyeing extract 32.03 Acaricides 38.08 Acaroid 13.01 Accelerometers (air navigational instruments) 90.14 Account books 4820.1 48.2 Accounting machines 84.7 84.7 1 Alphabetical Index: Bhutan Trade Classification, 2017 Explanatory Goods HS/BTC Code Notes Acenaphthene 29.02 Acenaphthenequinone 29.14 Acetaldehyde (ethanal) 2912.12 29.12 Acetaldoxime 29.28 Acetamide 29.24 Acetanhydride (acetic anhydride) 29- (E) List Acetanilide 29.24 Acetate pulp (wood pulp) 47.02 Acetate(s) 29.15 Acetic acid (including commercial) 2915.21 29.15 Acetic anhydride 2915.24 29- Prec. Acetic oxide 29- (E) List Acetification machines used in vinegar-making 84.38 Acetol 29.14 Acetone cyanohydrin 29.26 Acetone sodium bisulphite 29.05 Acetone 2914.11 29- Prec. Acetonylacetone 29.14 Narc.List Acetorphine (inn), acetorphine hydrochloride 2939.19 Acetoxime 29.28 2 Alphabetical Index: Bhutan Trade Classification, 2017 Explanatory Goods HS/BTC Code Notes Acet-p-phenetidide 29.24 29-Narc. Acetyldihydrocodeine, acetyldihydrocodeine hydrochloride List2939.19 Acetylene 29.01 Acetylenic hydrocarbons 29.01 Acetylides 28.49 Narc. Acetylmethadol (inn) List2922.19 Narc. Acetylmorphine, 3-acetylmorphine, 6-acetylmorphine List2939.10 Narc. Acetyl- -methylfentanyl α List2933.39 Aconite leaves and roots 12.11 Aconitine 29.39 Acorns 23.08 Acraldehyde (propenal) 29.12 Acridine and its derivatives (other than those constituting dyestuffs) 29.33 Acrolein (propenal) 29.12 Acrylaldehyde (propenal) 29.12 Acrylic acid and its salts 2916.11 29.16 Acrylic polymers 39.06 39.06 Acrylonitrile 2926.1 29.26 Acrylonitrile-butadiene-styrene (abs) copolymers 3903.3 39.03 Acth (adrenocorticotrophic hormone) 29.37 3 Alphabetical Index: Bhutan Trade Classification, 2017 Explanatory Goods HS/BTC Code Notes Actinium 28-I-Gen28.44 Actinomycins 29.41 Actinotherapy apparatus 90.18 Activated carbons (not being medicaments or put up for retail sale 3802.1 38.02 as deodorisers) Activated natural mineral products (e.g.,activated bauxite, 38.02 38.02 clays,diatomite, earths) Activin 29.37 Actuators, valve, electrical 85.01 Acupuncture needles 90.18 Adapters (laboratory glassware) 70.17 Adapters, cassette shaped 85.22 Adaptor units, for communication in a wired or wireless network 85.17 Address books 48.2 Address plate embossing machines 8472.9 Addressing machines 8472.9 84.72 Aden gum 13.01 Adenosine pyro- or tri-phosphoric acid 29.34 Adermin 29.36 Adipic acid, its esters and salts 2917.12 29.17 Adipoketone (cyclopentanone) 29.14 Adiponitrile 29.26 4 Alphabetical Index: Bhutan Trade Classification, 2017 Explanatory Goods HS/BTC Code Notes Adiposetten n 29- (P) List Adjusters, shelf, base metal 83.02 Adrenal (medulla) hormones 29.37 Adrenal cortical hormones and their derivatives 29.37 Adrenal corticosteroids 29.37 Adrenocorticotrophic hormone (acth) 29.37 Adrenocorticotrophin 29.37 Adrenosterone 29.37 Adzes (base metal hand tools) 82.01 Aeolian harps 92.02 Aerating machinery, for beverages 8422.3 84.22 Aerial(s), radio, etc., and parts for use therewith 8529.1 85.29 Aerological sounding apparatus 90.15 Aeroplanes 8802 88.02 Aerosol therapy apparatus (including generator type) 9019.2 90.19 Aesculetin 29.32 African piassava 14.03 After shave preparations (e.g., after shave lotions) 3307.1 33.07 Agar-agar 1302.31 13.02 Agave fibres prepared for textile use, raw or processed but not 53.05 spun 5 Alphabetical Index: Bhutan Trade Classification, 2017 Explanatory Goods HS/BTC Code Notes Agglomerated dolomite 2518.3 25.18 Agitators, for textile machines 84.48 A-hypophamin (oxytocin (inn)) 29.37 Aids, calfing, mechanical 90.18 Aids, electronic, for the blind 90.21 Aids, hearing (not including parts and accessories) 9021.4 90.21 Ailerons, for aircraft 88.03 Air, liquid or compressed 2853 28Gen28.53 Aircraft (see also aeroplanes) : XVII Gen88 Gen Airers, towel, electric, domestic 85.16 Airwheels, for windmills 84.12 Alachlor (iso) 2924.25 29.24 Alanine and b-alanine 29.22 Album(s) 4820.5 48.2 Albumenometers (laboratory glassware) 70.17 Albumin(s) 35.02 35.02 Alcoholometers 90.25 Alder, black (or alder buckthorn), extract of 13.02 Aldicarb (iso) 2930.8 Aldimines 29.25 6 Alphabetical Index: Bhutan Trade Classification, 2017 Explanatory Goods HS/BTC Code Notes Aldol 29.12 Aldosterone (inn) 29.37 Aldrin (iso) 2903.82 29.03 Alençon lace, textile 58.04 Aleppo galls 14.04 Alfalfa (lucerne) 12.14 12.14 Alfaprostol (inn) 29.37 Alfentanil hydrochloride 2933.33 Narc.List2933.3 Alfentanil (inn) 2933.33 3 Alga spinosa 13.02 Algarobilla pods 14.04 Algerian fibre 14.04 Alginic acid, esters and salts 39.13 39.13 Alidades (surveying instruments), whether or not with a telescope 90.15 Alizarin 32.04 Alkali amides 28.53 Alkali chloroaurates 28.43 Alkali metals 2805.11 28.05 Alkali thiomolybdates 28.42 2805.11 Or Alkaline-earth metals 28.05 2805.19 7 Alphabetical Index: Bhutan Trade Classification, 2017 Explanatory Goods HS/BTC Code Notes Alkaloid tannates 29.39 Alkaloids, natural or reproduced by synthesis, and their salts, ethers, 29.39 29 Gen29.39 esters and other derivatives Alkanet roots 14.04 Alkenna (colouring matter) 32.03 Alkyd resins 3907.5 39.07 Alkylenes, mixed 27.1 Allene (propadiene) 29.01 Psyc. Allobarbital aminophenazone List2933.54 Psyc. Allobarbital (inn) 2933.53 List2933.53 Alloying preparations, for steel-making 38.24 Alluvium 25.3 Allyl alcohol 29.05 Allylene (propyne) 29.01 Allylestrenol (inn) 29Gen29.37 Narc. Allylprodine (inn), allylprodine hydrochloride List2933.39 Aloin 29.38 Alpaca hair 51.02 Alphacetylmethadol (inn), l-alphacetylmethadol, alphacetylmethadol Narc.List2922.1 hydrochloride 9 Narc. Alphameprodine (inn) List2933.39 Narc. Alphamethadol (inn) List2922.19 8 Alphabetical Index: Bhutan Trade Classification, 2017 Explanatory Goods HS/BTC Code Notes Alpha-phenylacetoacetonitrile 2926.4 29.26 Narc. Alphaprodine (inn), alphaprodine hydrochloride List2933.39 Psyc. Alprazolam (inn) 2933.91 List2933.91 Alprostadil (inn) 29.37 Alsatian leaven 21.02 Altars, being furniture of ch. 94 94.03 Altazimuths (telescopes) 90.05 Alu black 32.06 Alum blocks (toilet preparations) 33.07 Alum(s) 2833.3 28-V-Gen28.33 Aluminates, metal 28.41 Aluminosilicates 2842.1 28.42 Alumstone 25.3 Alunite (alumstone) 25.3 Amalgam carriers, mallets and stoppers(dental instruments) 90.18 Amaryllis 6.01 Amatols 36.02 Ambari hemp (textile fibres 53.03 Ambergris 510 5.1 Amblyoscopes (ophthalmic instruments) 90.18 9 Alphabetical Index: Bhutan Trade Classification, 2017 Explanatory Goods HS/BTC Code Notes Ambrette (musk) seeds 12.11 Ambrettolide 29.32 Ambroid (agglomerated amber) 25.3 Americium 28-I-Gen28.44 Psyc. Amfepramone glutamate List2922.42 Psyc. Amfepramone resinate List3003.90 Psyc. Amfepramone (inn), amfepramone hydrochloride 2922.31 List2922.31 Amfetamine acetylsalicylate, adipate, p-chlorophenoxyacetate, Psyc. hydrochloride, hydrogen tartrate (bitartrate), phosphate, sulfate, List2921.46 tartrate Psyc. Amfetamine p-aminophenylacetate, aspartate List2922.49 Psyc. Amfetamine pentobarbiturate List2933.54 Psyc. Amfetamine resinate List3003.90 Psyc. Amfetamine tannate List3201.90 Psyc. Amfetamine (inn) 2921.46 List2921.46 Amides 29-IX-Gen29.24 Amidines 29.25 Amidopyrin 29.33 Amine-function compounds 29.21 Amines 29-IX-Gen29.21 Psyc. Aminorex 2934.91 List2934.91 Ammeters 90.3 10 Alphabetical Index: Bhutan Trade Classification, 2017 Explanatory Goods HS/BTC Code Notes Ammonals 36.02 Ammoniacal gas liquors from coal gas purification 38.24 Ammoniacal nickel nitrates 28.42 Ammonium nitrate fuel oil (anfo) 36.02 Psyc. List3003.9 Amobarbital resinate 0 Amobarbital sodium 2933.53 Psyc. Amobarbital (inn) List2933.53 Amoxillin (inn) 2941.1 29.41 Amperemeters 90.3 29 - (CS) Amphetamine (inn) List29.21 Amphotericin b 29.41 Ampicillin (inn) 2941.1 29.41 Amplifier sets, electric sound 8518.5 85.18 Amplifier tubes and valves, electronic 8540.81 Amplitude meters, for checking balance wheel oscillation 90.31 Ampoules, glass 7010.1 70.1 Amusements, fairground 9508 95.08 Amygdalin 29.38 Amylenes (pentenes) 29.01 Amylogen 35.05 11 Alphabetical Index: Bhutan Trade Classification, 2017 Explanatory Goods HS/BTC Code Notes Amyloglucosidases 35.07 Amylopectin (isolated), obtained by the fractionation of starch 39.13 Amylose (isolated), obtained by the fractionation of starch 39.13 Anacardium 13.01 Anaesthetic ether (diethyl ether) 29 - (E)List Anatase (titanium ore) 26.14 Anchovy paste 16.04 Andalusite, whether or not calcined 25.08 Andouillettes (meat sausages) 16.01 Androgens 29.37 Androst-4-ene-3,11,17-trione 29.37 Androst-4-ene-3,17-dione 29.37 Androst-5-ene-3 b,17 b -diol 29.37 Androst-5-ene-3 b,17 b -diol 29.37 Androstanolone (inn) 29.37 Androstenediols 29.37 Androsterone 29.37 Anemone (bulbous species) 6.01 Anethole 29.09 Aneurine naphthalene-1,5-disulphonate(thiamine-1,5-salt) 29.36 12 Alphabetical Index: Bhutan Trade Classification, 2017 Explanatory Goods HS/BTC Code Notes Aneurine salicylate hydrobromide (thiamine salicylate hydrobromide) 29.36 Aneurine salicylate hydrochloride(thiamine salicylate hydrochloride) 29.36 Aneurine (vitamin b1) 29.36 Aneurine-1,5-salt (thiamine-1,5-salt) 29.36 Anfo (ammonium nitrate fuel oil) 36.02 Angel(s), toy 95.03 Angledozers, self-propelled 84.29 84.29 Anglesite (lead ore) 26.07 Angora hair, of angora goats or rabbits (see also hair, animal) 51.02 Angostura bark 12.11 Angular grit, of iron or steel, graded or not 72.05 Anhydrite 2520.1 25.2 Anileridine dihydrochloride, phosphate 2933.33 Narc.
Recommended publications
  • (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao Et Al

    USOO9498481 B2 (12) United States Patent (10) Patent No.: US 9,498,481 B2 Rao et al. (45) Date of Patent: *Nov. 22, 2016 (54) CYCLOPROPYL MODULATORS OF P2Y12 WO WO95/26325 10, 1995 RECEPTOR WO WO99/O5142 2, 1999 WO WOOO/34283 6, 2000 WO WO O1/92262 12/2001 (71) Applicant: Apharaceuticals. Inc., La WO WO O1/922.63 12/2001 olla, CA (US) WO WO 2011/O17108 2, 2011 (72) Inventors: Tadimeti Rao, San Diego, CA (US); Chengzhi Zhang, San Diego, CA (US) OTHER PUBLICATIONS Drugs of the Future 32(10), 845-853 (2007).* (73) Assignee: Auspex Pharmaceuticals, Inc., LaJolla, Tantry et al. in Expert Opin. Invest. Drugs (2007) 16(2):225-229.* CA (US) Wallentin et al. in the New England Journal of Medicine, 361 (11), 1045-1057 (2009).* (*) Notice: Subject to any disclaimer, the term of this Husted et al. in The European Heart Journal 27, 1038-1047 (2006).* patent is extended or adjusted under 35 Auspex in www.businesswire.com/news/home/20081023005201/ U.S.C. 154(b) by Od en/Auspex-Pharmaceuticals-Announces-Positive-Results-Clinical M YW- (b) by ayS. Study (published: Oct. 23, 2008).* This patent is Subject to a terminal dis- Concert In www.concertpharma. com/news/ claimer ConcertPresentsPreclinicalResultsNAMS.htm (published: Sep. 25. 2008).* Concert2 in Expert Rev. Anti Infect. Ther. 6(6), 782 (2008).* (21) Appl. No.: 14/977,056 Springthorpe et al. in Bioorganic & Medicinal Chemistry Letters 17. 6013-6018 (2007).* (22) Filed: Dec. 21, 2015 Leis et al. in Current Organic Chemistry 2, 131-144 (1998).* Angiolillo et al., Pharmacology of emerging novel platelet inhibi (65) Prior Publication Data tors, American Heart Journal, 2008, 156(2) Supp.
  • Clomifene Citrate(BANM, Rinnm) ⊗

    Clomifene Citrate(BANM, Rinnm) ⊗

    2086 Sex Hormones and their Modulators Profasi; UK: Choragon; Ovitrelle; Pregnyl; USA: Chorex†; Choron; Gonic; who received the drug for a shorter period.6 No association be- 8. Werler MM, et al. Ovulation induction and risk of neural tube Novarel; Ovidrel; Pregnyl; Profasi; Venez.: Ovidrel; Pregnyl; Profasi†. tween gonadotrophin therapy and ovarian cancer was noted in defects. Lancet 1994; 344: 445–6. Multi-ingredient: Ger.: NeyNormin N (Revitorgan-Dilutionen N Nr this study. The conclusions of this study were only tentative, 9. Greenland S, Ackerman DL. Clomiphene citrate and neural tube 65)†; Mex.: Gonakor. defects: a pooled analysis of controlled epidemiologic studies since the numbers who developed ovarian cancer were small; it and recommendations for future studies. Fertil Steril 1995; 64: has been pointed out that a successfully achieved pregnancy may 936–41. reduce the risk of some other cancers, and that the risks and ben- 10. Whiteman D, et al. Reproductive factors, subfertility, and risk efits of the procedure are not easy to balance.7 A review8 of epi- of neural tube defects: a case-control study based on the Oxford Clomifene Citrate (BANM, rINNM) ⊗ Record Linkage Study Register. Am J Epidemiol 2000; 152: demiological and cohort studies concluded that clomifene was 823–8. Chloramiphene Citrate; Citrato de clomifeno; Clomifène, citrate not associated with any increase in the risk of ovarian cancer 11. Sørensen HT, et al. Use of clomifene during early pregnancy de; Clomifeni citras; Clomiphene Citrate (USAN); Klomifeenisi- when used for less than 12 cycles, but noted conflicting results, and risk of hypospadias: population based case-control study.
  • United States Patent (10) Patent No.: US 7,190,052 B2 Lindgren (45) Date of Patent: Mar

    United States Patent (10) Patent No.: US 7,190,052 B2 Lindgren (45) Date of Patent: Mar

    US0071900.52B2 (12) United States Patent (10) Patent No.: US 7,190,052 B2 Lindgren (45) Date of Patent: Mar. 13, 2007 (54) SEMICONDUCTOR DEVICES WITH OXIDE 5,516,721 A 5/1996 Galli et al. COATINGS SELECTIVELY POSITONED 5,683,946 A 1 1/1997 Lu et al. OVER EXPOSED FEATURES INCLUDING 5,776,829 A 7/1998 Homma et al. SEMCONDUCTOR MATERAL 6,022,814 A 2/2000 Mikoshiba et al. 6,045,877 A 4/2000 Gleason et al. (75) Inventor: Joseph T. Lindgren, Boise, ID (US) 6,174,8246,130,116 AB1 10/20001/2001 MichaelSmith et etal. al. 6, 197,110 B1 3/2001 Lee et al. (73) Assignee: Micron Technology, Inc., Boise, ID 6,251,753 B1 6/2001 Yeh et al. (US) (*) Notice: Subject to any disclaimer, the term of this (Continued) patent is extended or adjusted under 35 OTHER PUBLICATIONS U.S.C. 154(b) by 0 days. Schreiber, S.J. et al., “Low Temperature Deposition of Microcrystal line Silicon For Thin Film Transistors,' CUED Electronic Devices (21) Appl. No.: 10/454.256 and Materials Group, http://www2.eng.cam.ac.uk/~www-edm/ (22) Filed: Jun. 3, 2003 projects/lowtempdepf1.htm, prior to Sep. 2000, 2 pages. e as (Continued) (65) Prior Publication Data Primary Examiner T. N. Quach US 2004/OO33682 A1 Feb. 19, 2004 (74) Attorney, Agent, or Firm TraskBritt Related U.S. Application Data (57) ABSTRACT (62) Division of application No. 10/218.268, filed on Aug. 13, 2002, now Pat. No. 6,593,221. A semiconductor device structure includes a passivation layer through which only non-silicon-comprising structures (51) Int.
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al

    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
  • Chemical Compounds As Carcinogenic Agents Second Supplementary Report: Literature of 1938 and 1939 Biological Considerations

    Chemical Compounds As Carcinogenic Agents Second Supplementary Report: Literature of 1938 and 1939 Biological Considerations

    CHEMICAL COMPOUNDS AS CARCINOGENIC AGENTS SECONDSUPPLEMENTARY REPORT: LITERATURE OF 1938 AND 1939 J. W. COOK AND E. L. KENNAWAY (From the Royal Cancer Hospital (Free), London, and the University of Glasgow) BIOLOGICALCONSIDERATIONS (Continued from page 428, Jitly 1940) II. Action of Carcinogenic Compounds in Difierent Species and Tissues A number of reports of the action of carcinogenic compounds on human tis- sues have appeared. Klar (601) developed a nodule on the forearm after completion of a series of experiments with 3:4-benzpyrene. He applied a solution of the hydrocarbon (0.25 per cent in benzol) to the skin of mice with a paint brush and for at least part of the period wore rubber gloves. He also conducted experiments, of which no description is given, with the powdered hydrocarbon contained in a glass vessel. Three months after the completion of the experiments a small nodule appeared on the dorsum of the left forearm, This was excised in May 1938 and described by Professor Huckel as a “ so- called benign calcifying epithelioma.” The growth extended into the subcu- taneous fatty tissue; the connection with the superficial epithelium is not described nor is it evident in the two photomicrographs which illustrate the report. The author does not state his age. Gordonoff and Walthard (562) record the occurrence of a tumor in a labo- ratory assistant, aged forty-two, engaged in applying methylcholanthrene (0.3 per cent in benzol) to the skin of mice. The site was in the nasolabial fold, at a spot often touched by the patient when smoking. The microscopic ap- pearance was that of a “ still well delimited stage of an incipient squamous- cell sarcoma.” Cottini and Mazzone (479) deliberately applied 3 :4-benzpyrene ( 1 per cent in benzene) to the skin, generally of the arm or thigh, of 26 patients with various cutaneous diseases, usually daily for periods up to 120 days.
  • Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Classification of Medicinal Drugs and Driving: Co-Ordination and Synthesis Report

    Project No. TREN-05-FP6TR-S07.61320-518404-DRUID DRUID Driving under the Influence of Drugs, Alcohol and Medicines Integrated Project 1.6. Sustainable Development, Global Change and Ecosystem 1.6.2: Sustainable Surface Transport 6th Framework Programme Deliverable 4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Due date of deliverable: 21.07.2011 Actual submission date: 21.07.2011 Revision date: 21.07.2011 Start date of project: 15.10.2006 Duration: 48 months Organisation name of lead contractor for this deliverable: UVA Revision 0.0 Project co-funded by the European Commission within the Sixth Framework Programme (2002-2006) Dissemination Level PU Public PP Restricted to other programme participants (including the Commission x Services) RE Restricted to a group specified by the consortium (including the Commission Services) CO Confidential, only for members of the consortium (including the Commission Services) DRUID 6th Framework Programme Deliverable D.4.4.1 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Page 1 of 243 Classification of medicinal drugs and driving: Co-ordination and synthesis report. Authors Trinidad Gómez-Talegón, Inmaculada Fierro, M. Carmen Del Río, F. Javier Álvarez (UVa, University of Valladolid, Spain) Partners - Silvia Ravera, Susana Monteiro, Han de Gier (RUGPha, University of Groningen, the Netherlands) - Gertrude Van der Linden, Sara-Ann Legrand, Kristof Pil, Alain Verstraete (UGent, Ghent University, Belgium) - Michel Mallaret, Charles Mercier-Guyon, Isabelle Mercier-Guyon (UGren, University of Grenoble, Centre Regional de Pharmacovigilance, France) - Katerina Touliou (CERT-HIT, Centre for Research and Technology Hellas, Greece) - Michael Hei βing (BASt, Bundesanstalt für Straßenwesen, Germany).
  • LIGAND FORMULA INDEX CH5N 1 C3hlln3 68 CH603NP Z97 C3hll

    LIGAND FORMULA INDEX CH5N 1 C3hlln3 68 CH603NP Z97 C3hll

    LIGAND FORMULA INDEX CH5N 1 C3HllN3 68 CH 0 NP Z97 6 3 C3Hll °3Nl 304 C3HIZ0gNP3 319 C H O N 164 Z 3 Z 3 C3HIZ0l0NP3 3Z0 CZH4OZN4 164 C H N 335 Z 5 C4H304N3 343 C H 0 N 347 Z 5 Z Z C4H4NZ 263,263,264 C H 0N Z6 Z 6 Z C4H402N2 34Z C H O N Z 6 Z 4 56 C4H403NZ 34Z C H N Z,72 2 7 C4H5ON Z 264 C H NS 3Z Z 7 C4H6NZ 146,148,149,349 C H 0N 15 Z 7 C4H6ON Z 15Z,15Z C H 0 NS 10 Z 7 3 C4H7N3 155 C H 0 NS 331 Z 7 4 C4H9N 7,73 C H N 36 2 8 Z C4HgN3 S2 348 C H 0 NP Z 8 3 Z98,246 C4HgON 81 C H 0 NP 3Z9 Z 8 4 C4HgON 2 348 C4HgOZN Z4,333,333 C H N 144,349 3 4 Z C4HgOZNS 33 C3H7N 6,331,335 C4H9OZN3 28,348 C H 0 N 23 3 7 2 C4Hg03 N 18 C3H80N 79 C4H904N2 77 Z7,3L,7 C3H80N2 C4H10NZ 91 3,331 C3HgN C4Hl00ZNZ 59 33,%7 C3H9NS C4H1006NP 346 347 C3HgN3 S C4HllN 3,5,7Z,331,331 C H ON 3 g 16,16,21 C4Hll NS 348 C H O N 347 3 g Z C4HllON 17,79,115,33Z,33Z,347 10 C3Hg03 NS C4HllONS 35 C H N 39,51,8Z 3 10 Z C4HllOZN 19,80 C H ON 57 3 10 Z C4Hl103N ZO 298,300,301 C3HIOO3 NP C4Hll03NS 11 393 394 LIGAND FORMULA INDEX C4H1ZN2 40,40,41,42,S2,S4,83,88,lZ0 CsHn 02N3 29,29 C4H12N2S 6S C5H12NZ 91,92,124 C4H12NZS2 66 CSH120NZ 14 C4H1ZON 2 S8,9S CSH1202NZ 334 C4H1Z03NP Z99,346 CSH13N 4,331,33S C4H13N3 69,101 CSH130N 17,337 C4H1306NPZ 318 CSH130ZN 117,336,347 C4H1404Nl2 Z93 CSH1303NS 11 C4H1406NZPZ 30S CSH14NZ S3,SS,84,84,92,337 CSH140N Z 96,97,348,348 CSH3N4Cl 344 CSH1403NP 317,346 CSH4NBr 340,340 CSH140SNP 317 CSH4NCI 340,340 CSHlSN3 103,103 CSH4N4 344 CSH16 N4 71 CSH4N4S 344 CSH1709Nl3 346 CSH40N4 34S CSH40ZN4 34S C6H4N2 177,177 CSHSN 16S C6H4ON4 3S3 CSHSNS 276 C6H402N4 3S3 CSHSNSS
  • Hydrofluoric Acid Reduction Project – TURI Grant 2017

    Hydrofluoric Acid Reduction Project – TURI Grant 2017

    Hydrofluoric Acid Reduction Project – TURI Grant 2017 Sponsored by: Toxics Use Reduction Institute 126 John St Lowell, MA 01854 TURI Report 2018-001 Authors: Tyler DeFosse David Demarey Supervisor: Paul Watson Special Thanks to: Joy Onasch – Toxics Use Reduction Institute John Raschko – Massachusetts Office of Technical Assistance and Technology 1 Table of Contents 1.0 Executive Summary .......................................................................................................................... 3 2.0 Background ....................................................................................................................................... 5 2.1 Introduction ......................................................................................................................................... 5 2.2 Literature Searches .......................................................................................................................... 6 2.2.1 Diffusion Dialysis ...................................................................................................................... 6 2.2.2 Reverse Osmosis ....................................................................................................................... 7 2.2.3 Hydrofluoric Acid Wastewater Recycling Method ............................................................... 7 2.2.4 Issues Regarding the Etching of Silicon Dioxide ................................................................. 8 2.3 Alternative Strategies .....................................................................................................................
  • Walls and Fences: a Journey Through History and Economics

    Walls and Fences: a Journey Through History and Economics

    A Service of Leibniz-Informationszentrum econstor Wirtschaft Leibniz Information Centre Make Your Publications Visible. zbw for Economics Vernon, Victoria; Zimmermann, Klaus F. Working Paper Walls and Fences: A Journey Through History and Economics GLO Discussion Paper, No. 330 Provided in Cooperation with: Global Labor Organization (GLO) Suggested Citation: Vernon, Victoria; Zimmermann, Klaus F. (2019) : Walls and Fences: A Journey Through History and Economics, GLO Discussion Paper, No. 330, Global Labor Organization (GLO), Essen This Version is available at: http://hdl.handle.net/10419/193640 Standard-Nutzungsbedingungen: Terms of use: Die Dokumente auf EconStor dürfen zu eigenen wissenschaftlichen Documents in EconStor may be saved and copied for your Zwecken und zum Privatgebrauch gespeichert und kopiert werden. personal and scholarly purposes. Sie dürfen die Dokumente nicht für öffentliche oder kommerzielle You are not to copy documents for public or commercial Zwecke vervielfältigen, öffentlich ausstellen, öffentlich zugänglich purposes, to exhibit the documents publicly, to make them machen, vertreiben oder anderweitig nutzen. publicly available on the internet, or to distribute or otherwise use the documents in public. Sofern die Verfasser die Dokumente unter Open-Content-Lizenzen (insbesondere CC-Lizenzen) zur Verfügung gestellt haben sollten, If the documents have been made available under an Open gelten abweichend von diesen Nutzungsbedingungen die in der dort Content Licence (especially Creative Commons Licences), you genannten Lizenz gewährten Nutzungsrechte. may exercise further usage rights as specified in the indicated licence. www.econstor.eu Walls and Fences: A Journey Through History and Economics* Victoria Vernon State University of New York and GLO; [email protected] Klaus F. Zimmermann UNU-MERIT, CEPR and GLO; [email protected] March 2019 Abstract Throughout history, border walls and fences have been built for defense, to claim land, to signal power, and to control migration.
  • 540.14Pri.Pdf

    540.14Pri.Pdf

    Index Element names, parent hydride names and systematic names derived using any of the nomenclature systems described in this book are, with very few exceptions, not included explicitly in this index. If a name or term is referred to in several places in the book, the most informative references appear in bold type, and some of the less informative places are not cited in the index. Endings and suffixes are represented using a hyphen in the usual fashion, e.g. -01, and are indexed at the place where they would appear ignoring the hyphen. Names of compounds or groups not included in the index may be found in Tables P7 (p. 205), P9 (p. 232) and PIO (p. 234). ~, 3,87 acac, 93 *, 95 -acene, 66 \ +, 7,106 acetals, 160-161 - (minus), 7, 106 acetate, 45 - (en dash), 124-126 acetic acid, 45, 78 - (em dash), 41, 91, 107, 115-116, 188 acetic anhydride, 83 --+, 161,169-170 acetoacetic acid, 73 ct, 139, 159, 162, 164, 167-168 acetone, 78 ~, 159, 164, 167-168 acetonitrile, 79 y, 164 acetyl, III, 160, 163 11, 105, 110, 114-115, 117, 119-128, 185 acetyl chloride, 83, 183 K, 98,104-106,117,120,124-125, 185 acetylene, 78 A, 59, 130 acetylide, 41 11, 89-90,98, 104, 107, 113-116, 125-126, 146-147, acid anhydrides, see anhydrides 154, 185 acid halides, 75,83, 182-183 TC, 119 acid hydrogen, 16 cr, 119 acids ~, 167 amino acids, 25, 162-163 00, 139 carboxylic acids, 19,72-73,75--80, 165 fatty acids, 165 A sulfonic acids, 75 ct, 139,159,162,164,167-168 see also at single compounds A, 33-34 acrylic acid, 73, 78 A Guide to IUPAC Nomenclature of Organic actinide, 231 Compounds, 4, 36, 195 actinoids (vs.
  • Réglementation De La Pharmacie

    Réglementation De La Pharmacie

    R E C U E I L D E T E X T E S S U R L A P H A R M A C I E Mis à jour le 13 février 2017 par l’Inspection de la pharmacie P R É A M B U L E La réglementation relative à la pharmacie en vigueur en Nouvelle-Calédonie résulte de la coexistence des dispositions adoptées par la Nouvelle-Calédonie au titre de ses compétences en matières d’hygiène publique, de santé et de professions de la pharmacie1, et de celles adoptées par l’Etat au titre de ses compétences en matières de garanties des libertés publiques, de droit civil et de droit commercial2. Sur le contenu du recueil En 1954, la Nouvelle-Calédonie s’est vue étendre les articles L. 511 à L. 520 et L. 549 à L. 665 de l’ancien Livre V relatif à la Pharmacie du code de la santé publique métropolitain par la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du Code de la santé publique relatives à l'exercice de la pharmacie3, dont les modalités d’application ont été fixées par le décret modifié n° 55-1122 du 16 août 1955 fixant les modalités d'application de la loi n° 54-418 du 15 avril 1954 étendant aux territoires d'outre-mer, au Togo et au Cameroun certaines dispositions du code de la santé publique relatives à l'exercice de la pharmacie4. Depuis sont intervenues la loi- cadre Defferre5, la loi référendaire de 19886 et la loi organique n° 99-209 du 19 mars 1999 dont les apports ont eu pour résultat le transfert de ces articles de la compétence de l’Etat à la compétence de la Nouvelle-Calédonie, permettant à celle-ci de s’en approprier et de les modifier à sa guise par des délibérations du congrès de la Nouvelle-Calédonie7.
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&F1y3x PHARMACEUTICAL APPENDIX to THE

    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE